Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Quality of life in multiple myeloma: A scoping review

View Full Paper
Ask AI
Bookmark
Share

Authors

AXAoshuang XuHYHan YanQLQun Li

Discussion

Loading...

Member takes

Overview

Scoping review demonstrates therapy impacts on quality of life in multiple myeloma patients, suggesting treatment strategies may enhance outcomes.

Key Points

  • Quality of life improved during induction therapy in newly diagnosed multiple myeloma patients with specific regimens.
  • Daratumumab and ixazomib were associated with stable quality of life during maintenance across treatment arms.
  • Assessment included 25 clinical trials and observational studies, evaluating quality of life over time for multiple myeloma treatments.
  • Findings indicate the need for further research on novel agents and their effects on patient quality of life in multiple myeloma.

Cite This Study

Xu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7dchttps://doi.org/10.1182/blood-2025-2807
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY40322025
  2. 2Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma2025
  3. 3Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  4. 4Transition to IRD maintenance after DRD induction significantly deepens response in transplant-ineligible NDMM: A prospective multicenter study2025
  5. 5Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionals2025